WO1994017789A1 - Nanocapsules en polyalkylcyanoacrylate - Google Patents

Nanocapsules en polyalkylcyanoacrylate Download PDF

Info

Publication number
WO1994017789A1
WO1994017789A1 PCT/IE1993/000005 IE9300005W WO9417789A1 WO 1994017789 A1 WO1994017789 A1 WO 1994017789A1 IE 9300005 W IE9300005 W IE 9300005W WO 9417789 A1 WO9417789 A1 WO 9417789A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanocapsules
phase
active agent
dextran
polymerisation
Prior art date
Application number
PCT/IE1993/000005
Other languages
English (en)
Inventor
Valery Alexandrovich Dyatlov
Georgy Arkadievich Katz
Original Assignee
Shield Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shield Research Limited filed Critical Shield Research Limited
Priority to PCT/IE1993/000005 priority Critical patent/WO1994017789A1/fr
Priority to AU34621/93A priority patent/AU3462193A/en
Priority to EP93903290A priority patent/EP0683667A1/fr
Publication of WO1994017789A1 publication Critical patent/WO1994017789A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des nanocapsules ayant typiquement un diamètre compris entre 150 et 400 nm consistent en une phase contenue dans une enveloppe polymère formée d'un réseau de polymères. Les nanocapsules peuvent être utilisées pour encapsuler une gamme étendue d'agents actifs solubles dans l'eau en grande production pour la distribution d'un système cible ou d'un locus, par exemple des médicaments utilisés en thérapie ou en prophylaxie. Les nanocapsules peuvent être formées par polymérisation interfaciale d'alkyle-2-cyanoacrylates en un système à deux phases consistant en polymères solubles dans l'eau non miscibles, dans des conditions initiales de polymérisation, résultant en une encapsulation des agents actifs dans une enveloppe en polyalkylcyanoacrylate.
PCT/IE1993/000005 1993-02-15 1993-02-15 Nanocapsules en polyalkylcyanoacrylate WO1994017789A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/IE1993/000005 WO1994017789A1 (fr) 1993-02-15 1993-02-15 Nanocapsules en polyalkylcyanoacrylate
AU34621/93A AU3462193A (en) 1993-02-15 1993-02-15 Polyalkylcyanoacrylate nanocapsules
EP93903290A EP0683667A1 (fr) 1993-02-15 1993-02-15 Nanocapsules en polyalkylcyanoacrylate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IE1993/000005 WO1994017789A1 (fr) 1993-02-15 1993-02-15 Nanocapsules en polyalkylcyanoacrylate

Publications (1)

Publication Number Publication Date
WO1994017789A1 true WO1994017789A1 (fr) 1994-08-18

Family

ID=11042484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE1993/000005 WO1994017789A1 (fr) 1993-02-15 1993-02-15 Nanocapsules en polyalkylcyanoacrylate

Country Status (3)

Country Link
EP (1) EP0683667A1 (fr)
AU (1) AU3462193A (fr)
WO (1) WO1994017789A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (fr) * 1995-04-04 1996-10-10 Elan Corporation, Plc Nanoparticules biodegradables a liberation lente renfermant de l'insuline
WO1997049387A1 (fr) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particules comprenant des copolymeres amphiphiles, possedant un domaine d'enveloppe reticulee et un domaine de noyau utiles et autres dans des applications pharmaceutiques
US5932101A (en) * 1996-08-29 1999-08-03 Eastman Chemical Company Process for fluid/dense gas extraction under enhanced solubility conditions
WO2002039979A1 (fr) * 2000-11-17 2002-05-23 Centre National De La Recherche Scientifique (C.N.R.S.) Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US6506422B1 (en) 1996-08-30 2003-01-14 Nestec S.A. Nutritional formula for phenylketonuria patients
US6616946B1 (en) 1999-11-15 2003-09-09 Biocure, Inc. Triblock copolymer hollow particles for agent delivery by permeability change
WO2009135854A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d’agents biologiquement actifs
WO2009135853A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064967A1 (fr) * 1981-04-24 1982-11-17 N.V. Sopar S.A. Procédé de préparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064967A1 (fr) * 1981-04-24 1982-11-17 N.V. Sopar S.A. Procédé de préparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COLLOID AND POLYMER SCIENCE vol. 269, August 1991, pages 855 - 858 PONS, M.; ET AL. 'Influence of stabilizers on particle size and polydispersity of polybutyl- and polyisobutyl- cyanoacrylate nanoparticles' *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031231A1 (fr) * 1995-04-04 1996-10-10 Elan Corporation, Plc Nanoparticules biodegradables a liberation lente renfermant de l'insuline
US6491903B1 (en) 1996-06-27 2002-12-10 Washington University Particles comprising amphiphilic copolymers
WO1997049387A1 (fr) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particules comprenant des copolymeres amphiphiles, possedant un domaine d'enveloppe reticulee et un domaine de noyau utiles et autres dans des applications pharmaceutiques
US6383500B1 (en) 1996-06-27 2002-05-07 Washington University Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5932101A (en) * 1996-08-29 1999-08-03 Eastman Chemical Company Process for fluid/dense gas extraction under enhanced solubility conditions
US6106720A (en) * 1996-08-29 2000-08-22 Eastman Chemical Company Process for fluid/dense gas extraction under enhanced solubility conditions
US6506422B1 (en) 1996-08-30 2003-01-14 Nestec S.A. Nutritional formula for phenylketonuria patients
US6616946B1 (en) 1999-11-15 2003-09-09 Biocure, Inc. Triblock copolymer hollow particles for agent delivery by permeability change
FR2816949A1 (fr) * 2000-11-17 2002-05-24 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
WO2002039979A1 (fr) * 2000-11-17 2002-05-23 Centre National De La Recherche Scientifique (C.N.R.S.) Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
WO2009135854A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d’agents biologiquement actifs
WO2009135853A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
WO2009135854A3 (fr) * 2008-05-06 2010-11-04 Glaxo Group Limited Encapsulation d’agents biologiquement actifs
WO2009135853A3 (fr) * 2008-05-06 2011-05-12 Glaxo Group Limited Encapsulation d'agents actifs biologiquement
EP2441447A1 (fr) * 2008-05-06 2012-04-18 Glaxo Group Limited Encapsulation d agents actifs biologiquement

Also Published As

Publication number Publication date
EP0683667A1 (fr) 1995-11-29
AU3462193A (en) 1994-08-29

Similar Documents

Publication Publication Date Title
Matougui et al. Lipid-based nanoformulations for peptide delivery
EP0961612B2 (fr) Agents pharmaceutiquement actifs stabilises par proteine et leur utilisation
JP3695754B2 (ja) 医薬組成物に関する改良
US6623761B2 (en) Method of making nanoparticles of substantially water insoluble materials
US6749868B1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JP5405527B2 (ja) 薬理薬物の新規製剤、その製造法及びその使用法
JP3626184B2 (ja) 薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体
CA2058835C (fr) Composition pharmaceutique stable et methode pour la preparer
US20060078618A1 (en) Lipid particles and suspensions and uses thereof
IL156531A (en) We will use lipid particles, their preparation and pharmaceutical preparations that contain them
CN1303278A (zh) 制备水不溶性物质微粒的组合物和方法
JP2003500440A (ja) 不安定剤のサブミクロン粒子の製造方法
EP0682513A1 (fr) Nanocapsules de faible diametre, leur procede de preparation et leurs applications
JP2003501376A (ja) 疎水性薬物の持続性放出のための油コア組成物
Le Bourlais et al. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study
EP0683667A1 (fr) Nanocapsules en polyalkylcyanoacrylate
Pandey Solid lipid nanoparticles: a multidimensional drug delivery system
EP2696856A1 (fr) Formulation à libération contrôlée comprenant hcg
Umeyor et al. Important Pharmaceutical Applications of Man-Made Lipid Nanocarriers for Sustained Drug Delivery and Future Outlook
Yadav et al. A Review on Modern Formulation Approaches for Protein Based Drug Delivery
Gevariya et al. A review on recent trends in niosomal antiglaucoma drug delivery system
AU2015341479B2 (en) Oral administration of unstable or poorly-absorbed drugs
Souto et al. Lipid Matrix Nanoparticles in Diabetes
Gevariya et al. Niosome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CZ FI HU JP KR NO NZ PL RO RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: GE

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: GE

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 505211

Date of ref document: 19950815

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1993903290

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993903290

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993903290

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA